Fulvestrant

CHEMBL1358 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

606.8 g/mol

LogP

9.2

Phase

4

This injectable hormone therapy works by degrading estrogen receptors in cancer cells rather than merely blocking them, making it effective against hormone receptor-positive breast cancers that have stopped responding to other hormonal treatments. It is given as monthly injections into the muscle for postmenopausal women.

น้ำหนักโมเลกุล

606.8000 g/mol

LogP

9.20

TPSA

76.70 Å²

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Hypertension Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O

InChI

InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1

Molecular Formula

C32H47F5O3S

HBD / HBA

2 / 9

พันธะที่หมุนได้

14

อะตอมหนัก

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This injectable hormone therapy works by degrading estrogen receptors in cancer cells rather than merely blocking them, making it effective against hormone receptor-positive breast cancers that have stopped responding to other hormonal treatments. It is given as monthly injections into the muscle for postmenopausal women.

Yes, Fulvestrant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1358. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 104741. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Fulvestrant บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C32H47F5O3S
คำพ้องความหมาย: 1

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.